Skip to content

Legal status · United States

Is Mitoglitazone legal in the United States?

Written by Reviewed Sep 2026

Not approvedLongevityHuman studies cited: 4

Direct answer

No. Mitoglitazone is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.

Mitoglitazone in the United States at a glance

ClassificationInvestigational, not approved
FDA approval statusInvestigational, not approved. Completed phase 2 in type 2 diabetes (2011) and Alzheimer disease (2013) with results posted; no phase 3 registered. The lifespan extension is in male mice started at 7 months; the retest started at 18 months found no male benefit and shorter female lifespan.
Human studies cited4 of 8 citations on the profile
ReviewedSep 2026

Classification and note come from the Mitoglitazone profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.

What this means

  • 01

    Mitoglitazone is being studied in registered clinical trials but has not received FDA marketing approval in the United States.

  • 02

    Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.

  • 03

    Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.

What Mitoglitazone is

Extended male mouse median lifespan by 8.7 percent when started at 7 months, then failed a retest started at 18 months where it shortened female lifespan. In people it has completed a 356-patient phase 2b in type 2 diabetes and a 29-patient phase 2 in Alzheimer disease, both sponsor-run, neither followed by a phase 3.

Mitoglitazone is a thiazolidinedione designed to keep the insulin-sensitising effect of pioglitazone while largely avoiding the PPAR-gamma activation blamed for that class's fluid retention and weight gain. Its developer, Metabolic Solutions Development Company, traced the PPAR-gamma-independent action to a mitochondrial target it called mTOT, later identified as the mitochondrial pyruvate carrier (MPC1 and MPC2).

Mechanism: Mitoglitazone binds the mitochondrial pyruvate carrier complex (MPC1 and MPC2), identified by photo-crosslinking proteomics as the mitochondrial target of thiazolidinediones, and has minimal affinity for PPAR-gamma. Restricting pyruvate entry into mitochondria shifts fuel use and, in the developer's model, produces insulin sensitisation without the PPAR-gamma-driven fluid retention and adipose expansion.

Regulatory history: Investigational, not approved. Completed phase 2 in type 2 diabetes (2011) and Alzheimer disease (2013) with results posted; no phase 3 registered. The lifespan extension is in male mice started at 7 months; the retest started at 18 months found no male benefit and shorter female lifespan.

How FDA treats this kind of product

Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.

The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Mitoglitazone at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.

Mitoglitazone in other countries

Frequently asked questions

Is Mitoglitazone legal in the United States?

No. Mitoglitazone is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.

Can I buy Mitoglitazone in the United States?

No approved product exists to buy. In the United States Mitoglitazone is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.

Is Mitoglitazone FDA approved?

No. FDA status: Investigational, not approved. Completed phase 2 in type 2 diabetes (2011) and Alzheimer disease (2013) with results posted; no phase 3 registered. The lifespan extension is in male mice started at 7 months; the retest started at 18 months found no male benefit and shorter female lifespan.. Current US classification: "Investigational, not approved". On the evidence, 4 human studies are cited on its profile.

Related compounds in the United States

Full research profile

Mechanism, cited studies, FDA status and the full legal summary for Mitoglitazone live on its compound profile.

Mitoglitazone profile

This page is general information about the regulatory status of Mitoglitazone in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.